Interview with the Innovators

Supported by BridgeBio

Videos

Amyloidosis News presents a discussion on the evolving approaches to transthyretin stabilization for cardiac ATTR. Transthyretin amyloid specialists, Keyur B. Shah, MD, Section Chief of Heart Failure, Virginia Commonwealth University Health and Michel Khouri, MD, Associate Professor of Medicine in Cardiology, Duke University review cardiac ATTR mechanism of disease and discuss proven and potential approaches to TTR stabilization. Read More ›

The Journey to Diagnosing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Doesn’t Have to Be a Long One
Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL, discuss the debilitating disease burden and the pathway to transthyretin amyloid cardiomyopathy diagnosis. Read More ›

ATTR – A Disease of TTR Destabilization

Transthyretin (TTR) Protein in Humans: Stabilization vs Destabilization
In this first video clip, Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL; and Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX, describe the functions of transthyretin (TTR) in its naturally occurring tetrameric form and resulting damage from TTR destabilization. Read More ›

Serum Transthyretin in the Management of TTR Amyloidosis
Justin L. Grodin, MD, MPH, Assistant Professor of Medicine, UT Southwestern Medical Center, Dallas, TX, explains the current and potentially future utilities of serum transthyretin (sTTR) as a biomarker in the management of transthyretin amyloidosis. Read More ›

Setting Realistic Treatment Goals and Expectations for Patients with Transthyretin Amyloidosis
Ola Akinboboye, MD, MPH, MBA, Clinical Professor, Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health and Medical Director, Laurelton Heart Specialists PC (Rosedale, NY) and Clement C. Eiswirth, Jr., MD, FACC, Medical Director, Cardiomyopathy and Heart Failure Program, Ochsner Health, New Orleans, LA, highlight the importance of early diagnosis and realistic expectations for patients being treated for transthyretin amyloidosis. Read More ›

Recognizing Clinical Clues of ATTR-CM
Clement C. Eiswirth, Jr., MD, FACC, Medical Director, Cardiomyopathy and Heart Failure Program, Ochsner Health, New Orleans, LA, examines clinical hints for consideration in the diagnosis of ATTR-CM. Read More ›

Evoking Suspicion of ATTR-CM: Warning Signs
Clement C. Eiswirth, Jr., MD, FACC, Medical Director, Cardiomyopathy and Heart Failure Program, Ochsner Health, New Orleans, LA, offers warning signs of ATTR-CM to consider for patients with heart failure. Read More ›

Complexities of Transthyretin Amyloid Disposition
Joel N. Buxbaum, MD, Professor Emeritus, Molecular Medicine, The Scripps Research Institute, and Chief Medical Officer (consulting), Protego Biopharma, explores the mechanisms of organ damage in TTR amyloidosis (ATTR). This important information focuses on the biophysical and biochemical underpinnings of misfolded transthyretin (TTR) leading to tissue dysfunction in this disease. Read More ›

Transthyretin (TTR) Amyloidosis: Current Diagnostic Approaches in the Clinic
Justin L. Grodin, MD, MPH, Assistant Professor of Medicine, UT Southwestern Medical Center (Dallas, TX), presents a diagnostic algorithmic approach for the establishment of a firm diagnosis of ATTR, with a focus on ATTR patients with heart manifestations (cardiomyopathy). Read More ›

Page 1 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: